Compare GoPro Inc (GPRO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs Neurocrine Biosciences Inc — how do they compare? GoPro Inc trades at $0.63 (market cap $120.42M), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 139.2× GoPro Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| GPRO | NBIX | |
|---|---|---|
Market Cap | $120.42M | $16.76B |
Sector | Technology | Health |
52-Week High | $2.88 | $185.50 |
52-Week Low | $0.62 | $123.10 |
Enterprise Value | $168.37M | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.73, down 0.38% on the day, reflecting persistent financial distress. The stock is in a bearish technical trend, with negative earnings surprises in recent quarters and a net income margin of -20.7% for 2025. Revenue has declined from $1.1B in 2022 to $652M in 2025, while the company is actively pursuing strategic alternatives, including a potential sale, as announced in May 2026.
The outlook is highly speculative, hinging on the outcome of the strategic review. A successful sale could unlock value, but fundamental weaknesses—including cash burn, negative equity, and competitive pressures—pose significant risks. Analyst sentiment is mixed, with a majority Hold rating, indicating caution amid the binary event-driven thesis.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
